Hyperactivators of mammalian dendritic cells
AssigneeCorner Therapeutics, Inc.
InventorsKelsey K. FINN, Jonathan CHOW, Emily GOSSELIN, Dania ZHIVAKI
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to lysophosphatidylcholine (LPC) compounds and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells or canine dendritic cells. The present disclosure also relates to compositions comprising a LPC and one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.
Claims106
A composition comprising an isolated lysophosphatidylcholine (LPC) with a single acyl chain, and a TLR7/8 agonist, wherein the acyl chain is a C13-C24 acyl chain.
A composition comprising an isolated lysophosphatidylcholine (LPC) with a single acyl chain, and an antigen, wherein the acyl chain is a C21-C24 acyl chain.
A composition comprising an isolated lysophosphatidylcholine (LPC) with a single acyl chain, and dendritic cells, wherein the acyl chain is a C21-C24 acyl chain.
A method for production of hyperactivated dendritic cells, the method comprising contacting the dendritic cells with a composition comprising effective amounts of an isolated lysophosphatidylcholine (LPC) with a single C13-C24 acyl chain, and a TLR7/8 agonist for production of hyperactivated dendritic cells, wherein the hyperactivated dendritic cells secrete IL-1beta without undergoing pyroptosis.
A method of preparing an immunogenic composition, the method comprising:
- a) depleting leukocytes from a suspension of cells prepared from a tumor to obtain a tumor cell-enriched suspension;
- b) lysing cells from the tumor cell-enriched suspension to obtain a tumor cell lysate;
- and
- c) contacting the tumor cell lysate with an isolated lysophosphatidylcholine (LPC) having a single acyl chain and a toll-like receptor 7/8 (TLR7/8) agonist to obtain the immunogenic composition, wherein the acyl chain is a C13-C24 acyl chain.
A method of treating cancer, the method comprising:
- a) preparing an immunogenic composition comprising a tumor cell lysate, an isolated lysophosphatidylcholine (LPC) having a single acyl chain, and a toll-like receptor 7/8 (TLR7/8) agonist, wherein the tumor cell lysate is or has been prepared from a sample of a tumor obtained from the mammalian subject with cancer, and the acyl chain is a C13-C24 acyl chain;
- and
- b) administering to the subject an effective amount of the immunogenic composition.
A composition comprising an isolated lysophosphatidylcholine (LPC) with a single acyl chain, and a pathogen recognition receptor (PRR) agonist, wherein the acyl chain is a C13-C24 acyl chain.
A pharmaceutical formulation comprising an isolated lysophosphatidylcholine (LPC) with a single acyl chain, and a pharmaceutically acceptable excipient, wherein the acyl chain is a C21-C24 acyl chain.
A composition for hyperactivation of human dendritic cells, comprising an isolated lysophosphatidylcholine (LPC) with a single acyl chain, and a pathogen recognition receptor (PRR) agonist, wherein the acyl chain is C22 acyl chain, and wherein the composition is effective for achieving a higher level of dendritic cell hyperactivation than a comparator composition comprising PGPC in place of the LPC.
Dependencies are inferred from the claim text.